Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16896202 | 0.85 | TLR4 (0.76) | TLR4ALDH1A1LMNATP53MEN1 | |
| SCHEMBL16906388 | 0.85 | TLR4 (0.54) | TLR4SMN1; SMN2HPGDALDH1A1TGM2 | |
| SCHEMBL16896166 | 0.85 | TLR4 (0.56) | TLR4SMN1; SMN2HPGDALDH1A1TGM2 | |
| SCHEMBL16896039 | 0.82 | TLR4 (0.54) | TLR4SMN1; SMN2HPGDALDH1A1TGM2 | |
| SCHEMBL16896090 | 0.82 | TLR4 (0.53) | TLR4SMN1; SMN2HPGDALDH1A1ATM | |
| SCHEMBL14010913 | 0.73 | TGM2 (0.75) | SMN1; SMN2ALDH1A1TGM2LMNAMEN1 | |
| SCHEMBL16906383 | 0.73 | TLR4 (0.50) | TLR4TGM2POLBTP53MEN1 | |
| SCHEMBL16896188 | 0.72 | POLB (0.76) | ALDH1A1POLBLMNATP53KMT2A | |
| SCHEMBL16906386 | 0.72 | TLR4 (0.79) | TLR4SMN1; SMN2ALDH1A1LMNATP53 | |
| SCHEMBL16896088 | 0.72 | TLR4 (0.76) | TLR4SMN1; SMN2ALDH1A1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505768-B2 | Compositions and methods for modulating TLR4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-29 | — | — | US | disclosed |
| US-20150197527-A1 | COMPOSITIONS AND METHODS FOR MODULATING TLR4 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197527-A1 | COMPOSITIONS AND METHODS FOR MODULATING TLR4 | TLR4, TLR3, TLR6 | TLR4 1/4885SMN1; SMN2 4028/4885HPGD 3842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.